Science
Paolo Tarantino: Gedatolisib and Trastuzumab Combination in Pretreated MBC

Paolo Tarantino: Gedatolisib and Trastuzumab Combination in Pretreated MBC

Paolo Tarantino, Research Fellow Dana-Farber Cancer Institute and Harvard Medical Schoolpost, shared on X:

“Approximately 30% of HER2+ breast cancers harbor PIK3CA mutations.

In this interesting report just published in ESMO Open, gedatolisib + trastuzumab yielded an ORR of 43% and PFS 6 months for pretreated, PIK3CAm, HER2+ MBC. Key toxicity: stomatitis.”

Title: Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after two or more HER2-directed therapies

Authors: J. W. Kim, Y. H. Park, S. Lee, H. K. Ahn, J. Bae, S. Park, H. Chae, J. H. Kim, K.-H. Lee, M. H. Kim, K. E. Lee, M. J. Kang, I. H. Park, Y. S. Chae, G. W. Lee, K. U. Park, E. M. Lee, J. H. Park, J. E. Kim, H. J. Kim, T. H. Kim, S. Y. Oh, S. Ko, J. H. Byun, J. Y. Ha, J. H. Kwon, S. Lee, J. Y. Choi, J. Y. Jung, K. H. Park

Read the full article.Paolo Tarantino: Gedatolisib and Trastuzumab Combination in Pretreated MBC

Medically reviewed Jul 21, 2026 by Mariam Khachatryan, MD
Breast Cancer breast cancers cancer E. M. Lee ESMO Open G.-W. Lee H. Chae H.J. Kim H.K. Ahn I. H. Park J. Bae J. E. Kim J. H. Byun J. H. Kwon J. H. Park J. Y. Choi J. Y. Ha J. Y. Jung J.H. Kim J.W. Kim K. E. Lee K. U. Park K.-H. Lee K.H. Park M. J. Kang M.H. Kim OncoDaily Oncology Paolo Tarantino S. Ko S. Lee S. Park S.Y. Oh T. H. Kim Y. H. Park Y.S. Chae